extract: 2025-12-01-who-glp1-global-guidelines-obesity

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti
 
 MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO issued conditional recommendations (not full endorsements) for GLP-1s, acknowledging 'limited long-term evidence' and requiring countries to 'consider local cost-effectiveness, budget impact, and ethical implications.' The conditional framing and emphasis on budget impact analysis suggests WHO recognizes the chronic use economics challenge, particularly for low/middle-income countries where affordability barriers may be insurmountable.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the
 
 The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO's three-pillar framework for GLP-1 implementation explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. The framework states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical interventions alone cannot address health outcomes determined primarily by behavioral and social factors.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment
 PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
 EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic
+
+
+## Key Facts
+- WHO issued GLP-1 obesity treatment guidelines in December 2025
+- Guidelines use conditional recommendation framework acknowledging limited long-term evidence
+- WHO framework has three pillars: population policies, high-risk protection, person-centered care
+- Guidelines require countries to assess local cost-effectiveness and budget impact